Trinity Biotech Plc (TRIB) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access TRIB Annual Income Statement →
Income statement data covering Trinity Biotech Plc–Dec 31 2024 offers a view into how Dec 31 2025's operating results have moved alongside business activity.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2025)
Q4 2025
0 0 0 (Dec 31 2024)
Revenues
Total Revenue43.79
Costs & Expenses
Cost of Goods and Services Sold26.90
Gross Profit16.89
Selling, Administration, Marketing24.67
Research and Development Expense3.63
OtherOperating Income Expense4.37
Total operating costs including COS59.57
Operating income / -loss-15.79
Net Interest Expense / -Income0.00
Other loss / -income-21.39
Total costs & expenses80.96
Income & Taxes
Income / -loss before income taxes-37.18
Income taxes expenses / -benefit0.20
Income after income taxes-37.38
Income / -loss from continuing operations-37.38
Net income / -loss-37.38
Income / -loss to shareholder-37.38
EBIT-37.18
EBITD-35.88
EBITDA-34.49
Earnings Per Share
Basic EPS (excl. extra items)0.00
Basic Net EPS0.00
Diluted Net EPS0.00
4 historic quarters locked

Sign in to unlock the full Trinity Biotech Plc income statement history.

About TRIB Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.